Objective: To measure systemic haptoglobin (HPT) concentrations from birth in preterm (PT) and T newborns. To compare HPT in newborns without hemolysis or infection with values in bacteremic newborns.
Introduction
The acute phase reactant haptoglobin (HPT) is a plasma glycoprotein synthesized predominantly by the hepatocytes. 1 HPT binds free hemoglobin during hemolysis, preventing oxidative damage by reactive oxygen species and reducing iron loss through urinary excretion. 2 The HPT-hemoglobin complex is cleared after binding to the CD163 receptor on monocytes and macrophages. 3 The antioxidant and immunomodulatory effects of HPT are relevant in hemolytic and infectious diseases, diabetes mellitus, and renal and coronary artery diseases. 4 Systemic HPT concentrations are used clinically as a marker of hemolysis. 5 Decreased, often undetectable, HPT concentrations are found in patients with both intravascular as well as extravascular hemolysis. 6 Normal HPT concentrations in adults are higher than those in children. Published reference values for children at birth (in cord blood) are zero, whereas mean concentrations in newborns 1-to 7-day-old are reported at 10 mg dl À1 (range from 0 to 41 mg dl À1 ), and for those from 1 to 4 weeks of age are 28 mg dl À1 , with a range of 0 to 45 mg dl À1 . Infants between 6-and 12-month-old have mean HPT concentrations of 115 mg dl À1 (range from 43 to 160 mg dl À1 ). 7, 8 Most methods used previously have failed to consistently measure HPT in neonates, particularly at birth and in PT newborns, likely because of insufficient assay sensitivity. [9] [10] [11] Accurate determination of HPT in newborns is needed because of its potential utility in the clinical evaluation of hemolytic and inflammatory neonatal diseases. In this study, we measured HPT concentrations in preterm (PT) and term (T) newborns from birth, and compared them at different ages and clinical conditions. Methods PT (<36 weeks' gestation) and T (X37 to <42 weeks' gestation) neonates born at our institution between 1 January 2006 and 30 September 2007 were identified prospectively. Neonates from whom plasma and serum specimens were collected as part as their routine medical care (for example, to perform routine cord blood serologic testing, bilirubin measurements, electrolyte concentrations and so on) were identified. Specimens deemed no longer needed for patient care by the clinical laboratory from groups of neonates with samples collected at birth (cord blood), on days of life 2 to 4 (D2 to D4), and at 7 to 14 days of life (weeks 1 to 2) were stored at À80 1C for further testing in our laboratory. Clinical data including gender, gestational age, birth weight, laboratory data, delivery history and hospital course were obtained by review of both electronic and paper medical records from birth through 90 days of age, or to discharge, if earlier.
Our institution provides care to neonates delivered without medical complications, as well as to newborns with high-risk conditions, the latter admitted to our 83-bed, level III, neonatal intensive care unit staffed by several board-certified neonatologists available in-house 24/7. Neonates were classified as 'healthy' for the purpose of this study, if both hemolysis and infection were excluded according to documentation by our local neonatologists during their hospital stay. Hemolysis was excluded by a negative history of feto-maternal isoimmunization, a negative antibody screen at birth, a normal reticulocyte count whenever available within the first month of life, and by the absence of hydrops fetalis, phototherapy in the first 24 h of life, the need for transfusion, or the consideration of hemolytic disease by the treating neonatology team. Infection was excluded by the absence of bacteremia or another focus of infection, and by the lack of temperature instability, respiratory distress after initial resuscitation, lethargy, feeding intolerance or any other of sign of sepsis documented by the treating neonatologists. Babies with a confirmed history of chorioamnionitis documented in the medical chart were excluded.
HPT concentrations were measured in triplicate by enzyme-linked immunosorbent assay (ELISA) with a lowest limit of detection of 0.002 mg dl À1 (Assaypro, St Charles, MO, USA). Measurements were performed in groups of neonates at birth (cord blood), on D2 to D4 and at weeks 1 to 2. A separate group of bacteremic neonates were also identified to compare HPT concentrations in a systemic inflammatory condition. These neonates were classified as 'sick' in our study. C-reactive protein (CRP) plasma concentrations were measured to exclude newborns with values X6 mg dl À1 to further select patients with a low likelihood of bacterial infection.
12-14 CRP was measured either by the clinical laboratory, or by us in triplicate using ELISA (Assaypro) with a lowest limit of detection of 0.02 and 0.00001 mg dl
À1
, respectively. One sample per patient was included for all assays. Statistical analyses were performed with SAS v9.1 (SAS Institute, Cary, NC, USA). The University's Institutional Review Board approved the project and patient consent was waived.
Results
A total of 58 newborns had no evidence of hemolysis or infection and were therefore classified as healthy; 36 were male. In all, 30 were PT and 28 were T. Table 1 shows their gestational age and birthweight. Mean chronological age in days for the D2 to D4 and weeks 1 to 2 groups was 2.72 ± 0.51 s.d. (range from 2 to 3.6) and 7.51 ± 0.55 s.d. (range from 7 to 8.4), respectively. Median 1-min APGAR score for PT newborns was 8 (range from 4 to 9), and for T babies was 8 (range from 6 to 9). APGAR scores at 5 min had a median of 8 (range from 5 to 9) and 9 (range from 7 to 10) for PT and T neonates, respectively.
At delivery, 12 PT babies received surfactant. Six needed continuous nasal positive airway pressure, and three required endotracheal intubation, all for <24 h. One T newborn required transient endotracheal intubation to treat meconium aspiration. The remaining PT and T babies had uneventful births. Eighteen (60%) PT and one (3.6%) T newborns received systemic antibiotics empirically. Sixteen of these babies received antibiotics for p48 h, one PT baby was given antibiotics for 5 days, and two PT received them for 7 days. Infection was not confirmed in any of them. CRP concentrations were <1 mg dl À1 in 87.9% (n ¼ 51) of babies deemed without hemolysis or infection, the remaining seven neonates in this group had CRP concentrations between 1 and 5.71 mg dl À1 (median 2.33 mg dl À1 ). At birth, healthy PT and T newborns had similar median HPT concentrations in cord blood (5.90 mg dl À1 ; n ¼ 13, and 4.62 mg dl À1 ; n ¼ 21, respectively), as did newborns on D2 to D4 (26.93 mg dl À1 ; n ¼ 10, and 37.77 mg dl À1 ; n ¼ 7, respectively) (P>0.05). PT newborns at weeks 1 to 2 had median HPT concentrations of 3.43 mg dl À1 (n ¼ 7); no T babies remained hospitalized by weeks 1 to 2 ( Figure 1 ). Table 1 Gestational age and birth weight distribution among chronological age groups of preterm (PT) and term (T) newborns
Cord blood
Days 2-4 Weeks 1-2
Mean gestational age in weeks ± s. Figure 1 Haptoglobin concentrations in preterm (PT) and term (T) newborns without hemolysis or infection. Median haptoglobin concentrations in groups of PT (light bars) and T (dark bars) newborns measured at different chronological ages. *P ¼ 0.009 for PT babies on D2 to D4 vs cord blood, P ¼ 0.013 for PT babies on D2 to D4 vs weeks 1 to 2 and þ P ¼ 0.001 for T babies on D2 to D4 vs cord blood (Wilcoxon-Mann-Whitney test).
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HPT concentrations in T newborns on D2 to D4 were significantly higher than in T newborns at birth (P ¼ 0.001). PT newborns' HPT concentrations on D2 to D4 were significantly higher than in the group of PT babies at birth (P ¼ 0.009), and those at weeks 1 to 2 (P ¼ 0.013).
We additionally examined HPT concentrations in seven PT and one T bacteremic newborns. Pathogens included Escherichia coli (n ¼ 7), and Listeria monocytogenes (n ¼ 1). Five of these sick newborns with bacteremia (median age 2 days, range from 1 to 13 days) had median HPT concentrations of 98. 59 
Discussion
In contrast to previous reports, we demonstrate that HPT concentrations can be consistently measured from birth in both PT and T neonates. The ability to measure HPT even at this early time point likely reflects the greater sensitivity of ELISA as compared with other methods. For example, nephelometry failed to detect HPT consistently within 24 h of birth in healthy PT and T newborns. 9 Electrophoresis did not detect HPT shortly after birth in five (one T and four PT) healthy neonates. 11 More recently, T newborns without hemolysis or infection had HPT concentrations measured inconsistently by a photometric assay at birth, with values reported between 0 and 13.6 mg dl
À1
. 10 HPT concentrations reported, herein, for our healthy T neonates on D2 to D4, compare with previous reports. Cakmak et al. 10 reported mean HPT concentrations of 31.1±34.4 s.d. in T newborns at 5 days old whereas Linder et al. 15 reported concentrations of 46.5 mg dl À1 (±7.5 s.e.m.) for 12 normal neonates on the third day of life. Although HPT concentrations are known to increase gradually during infancy, 9 data to establish reference values in PT or T neonates are very scarce. In other species, HPT is known to have a biphasic response in the first few weeks of life, with low concentrations after an initial increase. 16 Such a biphasic response would explain the lower concentrations in PT babies at weeks 1 to 2 compared with those at D2 to D4. Other acute phase reactants are known to have a biphasic response in noninfected newborns shortly after birth. Procalcitonin, for example, has a peak value that occurs >24 h after birth, and values then decrease after 48 to 72 h of life in both PT and T neonates. 17 Our study focused on newborns without hemolysis or infection who were born at our institution and remained hospitalized shortly after birth. Only PT babies remained in the hospital beyond the first 72 h of life because of feeding and social-related issues, therefore, the lack of a group of T babies in our study with available samples at weeks 1 to 2. We speculate that after this initial biphasic response observed in the first few days after birth, HPT concentrations gradually increase to reach those reported in older children and adults.
Our group of neonates classified as healthy included babies who received antibiotics empirically, mainly in the PT group. Although antibiotics could potentially have an impact modifying the course of an infection and therefore the host response to it, we believe that our babies were free of infection despite having received antibiotics based on their clinical presentation, evolution and laboratory markers. All of the neonates included in our study that received empiric antibiotic therapy did so for a short time, which would be insufficient to treat a serious bacterial infection in the neonate, and all had a favorable outcome under close observation by our neonatologists.
The use of empiric short-term antibiotic therapy immediately after birth, particularly in PT infants is a common practice in many institutions. Our study is not large enough to detect possible significant differences in HPT concentrations between babies who received antibiotics vs those who did not. Despite this, we believe that the data we present significantly contributes to establish neonatal HPT reference values for babies in whom infection has been reasonably excluded by real-life clinical practice.
Bacteremic newborns in our study showed HPT levels greater than noninfected babies at any chronological age, except for those who died of fulminant sepsis. HPT has been studied as an acutephase reactant in neonates with sepsis. Other researchers detected HPT non-quantitatively in eight septic newborns but not in five noninfected newborns. 11 We provide further evidence that, regardless of gestational age, increased HPT concentrations are associated with the neonatal response to bacteremia.
The exact role of HPT in the neonatal response to systemic infection has not been fully elucidated. The HPT increase in bacteremic newborns is likely related to IL-6, a multifunctional cytokine that induces HPT synthesis, and that has been evaluated in the diagnosis of neonatal sepsis. [18] [19] [20] [21] [22] Circulating HPT is internalized by CD163, a receptor present mainly on monocytes and macrophages. CD163 binds toxic HPT-hemoglobin complexes, and it acts also as an immunomodulator. 23, 24 A predominantly anti-inflammatory role by HPT is suggested by its suppressive effect on lymphocyte and monocyte responses. 25, 26 HPT appears to be a key factor of the neonate's immune system to control the adverse effects of inflammation. An inadequate inflammatory response carries a poor clinical prognosis. Newborns with fulminant sepsis demonstrate no elevation of acute phase markers; 27 consistent with the lack of HPT elevation in the neonates who died with bacteremia in our study.
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S Chavez-Bueno et al Measurement of systemic concentrations of different inflammatory markers in newborns has been used as a diagnostic tool in newborns in whom sepsis is suspected. 28 Although it is unlikely that a single marker of inflammation would be sufficient to diagnose sepsis in newborns accurately and in a timely manner, HPT is a neonatal acute phase reactant that could potentially be used in combination with other laboratory and clinical parameters for the evaluation of neonatal sepsis.
HPT is a participant of the neonatal inflammatory response to sepsis in both PT and T infants. Neonatal HPT concentrations measured accurately from birth may be useful clinically in the evaluation of newborns with inflammatory conditions such as sepsis. The diagnosis and evaluation of neonatal hemolytic disease can also be challenging, and laboratory markers in addition to bilirubin concentrations and other traditional methods are needed. Carboxihemoglobin concentrations, for example, have been used in the evaluation of hemolysis associated to ABO incompatibility and glucose-6-phosphate dehydrogenase deficient in newborns. 29, 30 HPT could also potentially be used in the evaluation of neonatal hemolysis. Our results indicate the need for a more thorough analysis of neonatal HPT concentrations using ELISA.
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